NRIX

ANALYST NOTE: NURIX THERAPEUTICS, INC. (NRIX) DATE: 2026-06-13 CURRENT PRICE: $17.55

1. Structural Readiness

• State: Context-Only (No defined structural coil formation detected in the provided data).
• Conservative Entry: — (No entry level defined due to lack of structural setup).
• Breakout Level: — (No resistance level defined).
• Current Price: $17.55.
• Extension: — (No reference point for extension calculation).
• ATR Context: Current ATR is 6.7% (Very High). This indicates elevated volatility, consistent with a clinical-stage biotech where binary event risk (data readouts, FDA decisions) drives price swings.
• Classification: The setup is NOT a confirmed active coil, NOT a forming coil, and NOT invalidated. It is a Context-Only state. The price is trading near the recent January 2026 ATM issuance price of $18.25, suggesting a lack of significant technical structure formation post-issuance.

2. Thesis Layer

• Primary Secular Thesis: Biotech & GLP-1 → Oncology (Tier Direct).
• Thesis Weighting: High.
• Exposure Analysis: Nurix is a direct beneficiary of the "Targeted Protein Degradation" (TPD) thesis within the oncology sector. The company is not merely a participant but a platform leader in this specific modality.
• Directness: The company's core value proposition relies on degrading BTK (Bruton's tyrosine kinase) in patients who have failed standard-of-care BTK inhibitors (covalent and non-covalent) and BCL2 inhibitors. This addresses a critical unmet need in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
• Tailwinds: The secular trend of moving beyond small-molecule inhibitors to degraders in hematologic malignancies provides a structural tailwind. The company's partnerships with Gilead, Sanofi, and Pfizer validate the platform's utility, creating a "multiple waves" exposure where platform success drives multiple asset value.

3. The Business

• Company Role: Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines.
• Business Model: The company operates on a hybrid model:
• Internal Pipeline: Developing proprietary degraders (e.g., bexobrutideg, zelebrudomide) for internal commercialization or partnership.
• Platform Licensing: Leveraging its DEL-AI (DNA-Encoded Library - Artificial Intelligence) platform to generate drug discovery assets for large pharma partners (Gilead, Sanofi, Pfizer) in exchange for upfront fees, milestones, and royalties.
• Key Assets & Status (as of 2026-06-13):
• Bexobrutideg (NX-2127): A covalent BTK degrader. As of April 2026, the company is conducting a Phase 2 study (DAYBreak CLL-201) in triple-exposed CLL patients (failed cBTKi, ncBTKi, and BCL2i). This study is designed as a potentially pivotal trial for Accelerated Approval in the US, utilizing a 600mg once-daily dose determined by Phase 1b data. Enrollment commenced in October 2025.
• Zelebrudomide (NX-5948): A B-cell malignancy degrader. Enrollment recommenced in August 2024 following an FDA partial hold resolution. The company is conducting a Phase 1a/1b dose-escalation study.
• Pipeline Expansion: Management expects to commence enrollment of additional trials in 2026 to support registration in multiple jurisdictions. They also intend to explore utility in autoimmune and inflammatory diseases in 2026, requiring a separate IND.
• Financial Position:
• Collaboration Revenue: As of November 30, 2025, the company has received $482.0 million in non-dilutive financing.
• Future Potential: Eligible for up to $6.1 billion in future fees, milestones, and royalties.
• Recent Capital: In January 2026, the company raised $18.3 million via an ATM offering at $18.25/share.
• Market Context: The BTK inhibitor market was approximately $10.6 billion in 2024, with over 20,000 new CLL diagnoses and 80,000 NHL diagnoses in the US in 2024.

4. Archetype and Conviction

• Archetype: Growth Leader / Clinical Catalyst.
• The company fits the "Growth Leader" archetype within the biotech sector, driven by the potential of a pivotal Phase 2 readout for bexobrutideg. It is not a deep value recovery (no prior commercial success to recover from) nor a cyclical recovery. It is a high-beta growth story dependent on clinical data.
• Valuation Context:
• Financial Spine: Forward consensus EPS for FY1 is -2.63 and FY2 is -2.55. The company is pre-revenue (commercially) and burning cash, relying on collaboration milestones and equity raises.
• Conviction Stack:
• Thesis Strength: High. The TPD modality is a recognized next frontier, and the specific indication (triple-exposed CLL) is a high-value, underserved market.
• Evidence Quality: Strong. Multiple primary filings (E1-E16) confirm active pivotal trials, FDA alignment on dosing, and significant partner backing.
• Structural Quality: Moderate. The recent equity issuance (Jan 2026) and high ATR (6.7%) suggest volatility and potential dilution risk, but the capital raise ($18.3M) provides near-term runway.
• Setup Readiness: Low. There is no technical "coil" or consolidation pattern visible in the provided data; the stock is in a "context-only" state, likely reacting to the passage of time toward the pivotal data readout.
• Rerating Potential: High, contingent on the Phase 2 data supporting Accelerated Approval.

5. Invalidations, Strengtheners, and Gaps

• Invalidation Factors:
• Clinical Failure: If the Phase 2 DAYBreak CLL-201 trial fails to meet primary endpoints or shows unacceptable toxicity at the 600mg dose.
• Regulatory Setback: If the FDA rejects the Accelerated Approval pathway or the 600mg dose selection.
• Capital Exhaustion: If the $18.3M raised in Jan 2026 is insufficient to reach the next data readout, forcing a dilutive raise at depressed prices.
• Strengtheners:
• Positive Data Readout: Top-line data from the Phase 2 study showing high response rates in triple-exposed patients.
• New Partnerships: Announcement of additional collaborations leveraging the DEL-AI platform.
• IND Approval: Successful filing and acceptance of the IND for the autoimmune program.
• Evidence Gaps:
• Specific Data Points: No specific efficacy numbers (ORR, DOR) from the Phase 2 study are available as of the event date; the study is ongoing.
• Cash Runway: While total non-dilutive financing is known, the exact burn rate and remaining cash runway as of June 2026 are not explicitly detailed in the provided evidence (only the Jan 2026 raise amount is known).
• Competitive Landscape: No specific data on competitor pipeline status in the triple-exposed CLL space as of June 2026.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Phase 2 pivotal trial for bexobrutideg in triple-exposed CLL is active and FDA-aligned for Accelerated Approval; $6.1B potential milestone value from strategic partners; $482M non-dilutive financing received to date. Key risks: Binary clinical failure in Phase 2 trial; high volatility (6.7% ATR) and recent equity dilution; cash runway uncertainty relative to burn rate; regulatory rejection of dose or approval pathway. Sizing hint: Position size should be limited due to binary event risk and lack of technical setup; treat as a high-conviction binary bet rather than a trend-following position. Expected path: Price will likely remain range-bound or volatile until the Phase 2 data readout, with potential for significant expansion if data supports Accelerated Approval. Expected horizon: 12 to 24 months for the pivotal data readout and subsequent regulatory decision. Failure mode to watch: FDA communication indicating the 600mg dose is insufficient or the trial design is inadequate for Accelerated Approval.